drugset / Trial / NCT03999697
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Phase 1
Unknown
10 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
Timeline
- Start
- 2018-12-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous-derived CD22-targeted CAR-T cells | Cell therapy | — | Other |